Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Inclusion criteria: * Signed and dated written informed consent. * Male or female patients diagnosed with type 1 diabetes (T1D) at least 6 months prior to informed consent or type 2 diabetes (T2D) or non-diabetic obese patients. * T1D patients must use and be willing of and be willing to continue throughout the duration of the trial either: * multiple daily injections of insulin OR * continuous sub-cutaneous insulin infusion of any insulin type, with at least 3 months experience * For patients with T1D or T2D,HbA1c of 6.5 - 11% * Age at least 18 years of age * Body mass index of \>=18.5 kg/m\^2 * Estimated glomerular filtration rate greater than or equal to 60 ml/min/1.73m2 * Blood pressure greater than 90 /60 mmHg and less than or equal to 140 / 90 mmHg * Use of a highly effective method of contraception. * Further inclusion criteria apply Exclusion criteria: * For patients with T1D, treatment with an antihyperglycaemic agent within 3 months prior to visit 1 * occurrence of severe hypoglycaemia within 3 months prior to visit 1 * hypoglycaemic unawareness within 3 months prior to visit 1 * occurrence of diabetic ketoacidosis within 3 months of visit 1 and until visit 3 Further exclusion criteria apply